Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody and a potent Notch pathway inhibitor, demonstrating efficacy in various cancer models both as a monotherapy and in conjunction with chemotherapy agents.

Demcizumab (0-100 μg/mL) specifically binds to human DLL4, blocking its interaction with the Notch1 receptor in FACS binding assays[3]. Treatment with Demcizumab at 20 μg/mL for 48 hours reduces HES1 and DTX1 mRNA expression in PDTALL cells[4]. Additionally, Demcizumab (0-80 μg/mL, 1, 2, or 3 days) induces cell death and early apoptosis in PDTALL13 cells[4].

Demcizumab (10 mg/kg, i.p., once weekly) combined with Irinotecan (7.5 mg/kg) shows substantial antitumor activity in KRASWT and KRASMT colorectal cancer xenograft models[2]. Demcizumab, both as monotherapy or with Irinotecan (7.5 mg/kg), is effective against OMP-C8 colon tumors[3]. Administration of Demcizumab (20 mg/kg/week, intraperitoneal injection) enhances the survival rate of NRG mice injected with irradiated PDTALL13 cells[4].

Human

Monoclonal

Unconjugated